HMG-CoA还原酶特异性抑制剂为高脂血症和动脉粥样硬化的治疗提供了一个新方法。该类药物具有肝脏选择性,可抑制肝脏胆固醇合成,不良反应发生率低。该类药物包括亲脂性的洛伐他汀、辛伐他汀(非活性的内酯形式)、亲水性的普伐他汀(活性开环羟基酸形式)和兼有亲脂、亲水性的氟伐他汀(活性β-羟基酸形式)。其中亲脂性较弱的化合物(普伐他汀和氟伐他汀)肝脏选择性更大。 HMG-CoA reductase-specific inhibitors provide a new approach to the treatment of hyperlipidemia and atherosclerosis. Such drugs have liver selectivity, can inhibit liver cholesterol synthesis, the incidence of adverse reactions is low. Such drugs include lipophilic lovastatin, simvastatin (inactive lactone form), hydrophilic pravastatin (active open-celled hydroxy acid form), and lipophilic and hydrophilic fluvastatin Statin (active beta-hydroxy acid form). Among the less lipophilic compounds (pravastatin and fluvastatin), the liver is more selective.